Using a Revenue DCF model with operating margin convergence from -7712.0% to a target of 13.3% over 5 years, discounted at a WACC of 8.7%, Inhibikase Therapeutics, Inc. (IKT) has an intrinsic value of $4.46 per share (range: $2.62 – $5.85).
Using a Revenue DCF model with operating margin convergence from -7712.0% to a target of 13.3% over 5 years, discounted at a WACC of 8.7%, Inhibikase Therapeutics, Inc. (IKT) has an intrinsic value of $336.73 per share (range: $229.18 – $564.33).
Using the industry peer median EV/Revenue multiple (trailing + forward), Inhibikase Therapeutics, Inc. (IKT) has a fair value of $2.43 based on 2 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Inhibikase Therapeutics, Inc.IKT | 10 | 6.5x | 4.5x |
| Surrozen, Inc. | 205 | 35.2x | 17.0x |
| Agenus Inc. | 145 | 4.2x | 2.6x |
| Industry Median | 19.7x | 9.8x | |
| (*) Revenue | 0 | 0 | |
| = Enterprise Value | 5 | 4 | |
| (-) Net Debt | -9 | -9 | |
| Equity Value | 14 | 12 | |
| (/) Outstanding shares | 5 | 5 | |
| Fair Price | $3 | $2 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.